These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 26887826)

  • 1. Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when?
    Ziemssen F; Bartz-Schmidt KU; Dimopoulos S
    Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):615-6. PubMed ID: 26887826
    [No Abstract]   [Full Text] [Related]  

  • 2. Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to ocriplasmin therapy?
    Dimopoulos S; Bartz-Schmidt KU; Gelisken F; Januschowski K; Ziemssen F
    Br J Ophthalmol; 2015 Mar; 99(3):350-3. PubMed ID: 25342274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oct-based interpretation of the vitreomacular interface and indications for pharmacologic vitreolysis.
    Stalmans P; Duker JS; Kaiser PK; Heier JS; Dugel PU; Gandorfer A; Sebag J; Haller JA
    Retina; 2013; 33(10):2003-11. PubMed ID: 23881226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outer retina reflectivity changes on sd-oct after intravitreal ocriplasmin for vitreomacular traction and macular hole.
    Quezada-Ruiz C; Pieramici DJ; Nasir M; Rabena M; Steinle N; Castellarin AA; Dhoot D; Couvillion S; See RF; Avery RL
    Retina; 2015 Jun; 35(6):1144-50. PubMed ID: 25961122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Efficacy and Safety Profile of Ocriplasmin in Vitreomacular Interface Disorders.
    Shaikh M; Miller JB; Papakostas TD; Husain D
    Semin Ophthalmol; 2017; 32(1):52-55. PubMed ID: 27786583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
    Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EXPERIENCE WITH OCRIPLASMIN IN PATIENTS WITH VITREOMACULAR TRACTION SYNDROME: A RETROSPECTIVE STUDY OF 10 PATIENTS.
    Bormann C; Apitzsch BC; Habermann A; Hammer U; Hammer T
    Retin Cases Brief Rep; 2020; 14(4):377-380. PubMed ID: 29621042
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incomplete release of vitreomacular attachments after intravitreal ocriplasmin.
    Jeng KW; Baumal CR; Witkin AJ; Witkin SR; Wiegand TW; Waheed NK
    Ophthalmic Surg Lasers Imaging Retina; 2015 Feb; 46(2):271-4. PubMed ID: 25707057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial experience with ocriplasmin in the treatment of vitreomacular traction.
    Garcia JM; Isaac DL; Ávila M
    Arq Bras Oftalmol; 2016 Apr; 79(2):85-7. PubMed ID: 27224069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.
    Modi YS; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):677-9. PubMed ID: 26114851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved efficacy of ocriplasmin for vitreomacular traction release and transient changes in optic disk morphology.
    Willekens K; Abegão Pinto L; Vandewalle E; Stalmans I; Stalmans P
    Retina; 2015 Jun; 35(6):1135-43. PubMed ID: 25719990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does ocriplasmin affect the RPE-photoreceptor adhesion in macular holes?
    Hager A; Seibel I; Riechardt A; Rehak M; Joussen AM
    Br J Ophthalmol; 2015 May; 99(5):635-8. PubMed ID: 25403647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ANATOMICAL AND FUNCTIONAL OUTCOMES OF SYMPTOMATIC IDIOPATHIC VITREOMACULAR TRACTION: A Natural History Study From the Pan American Collaborative Retina Study Group.
    Wu L; Zas M; Berrocal MH; Arevalo JF; Figueroa M; Rodriguez F; Serrano M; Graue F; Alezzandrini A; Gallego-Pinazo R; Roca JA; Iglicki M; Dalma-Weishauz J; Kozak I; Collado A; Badal J; Maia M; Salcedo-Villanueva G; Quiroz-Mercado H; Fromow-Guerra J; Lozano-Rechy D; Avila M; Chhablani J
    Retina; 2016 Oct; 36(10):1913-8. PubMed ID: 26966868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.
    Abou Ltaif S; Herbert L
    BMJ Case Rep; 2015 Sep; 2015():. PubMed ID: 26359463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical management of vitreomacular traction.
    Khan MA; Haller JA
    Curr Opin Ophthalmol; 2015 May; 26(3):143-8. PubMed ID: 25784108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. REVISED PREDICTIVE BIOMARKER FOR OCRIPLASMIN THERAPY IN VITREOMACULAR TRACTION DISORDERS.
    Al-Nawaiseh S; Rickmann A; Seuthe AM; Al-Rimawi D; Viktor Stanzel B; Szurman P
    Retina; 2021 Dec; 41(12):2549-2555. PubMed ID: 34173361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EFFICACY AND SAFETY OF TREATMENT OPTIONS FOR VITREOMACULAR TRACTION: A Case Series and Meta-Analysis.
    Yu G; Duguay J; Marra KV; Gautam S; Le Guern G; Begum S; Sharifzadeh A; Arroyo JG
    Retina; 2016 Jul; 36(7):1260-70. PubMed ID: 26783988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
    Varma R; Haller JA; Kaiser PK
    JAMA Ophthalmol; 2015 Sep; 133(9):997-1004. PubMed ID: 26068086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel possibility of vitreomacular traction treatment.
    Michalska-Małecka K; Witek K; Sierocka-Stępień J; Wyględowska-Promieńska D; Nowak M
    Acta Ophthalmol; 2016 Dec; 94(8):e818-e819. PubMed ID: 27167161
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmaological vitreolysis with ocriplasmin as a treatment option for symptomatic focal vitreomacular traction with or without macular holes (≤400 μm) compared to tranconjunctival vitrectomy].
    Maier M; Abraham S; Frank C; Lohmann CP; Feucht N
    Ophthalmologe; 2017 Feb; 114(2):148-154. PubMed ID: 27444007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.